FATE
Fate TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
FATE vs peer average
92/100
FATE vs. peer average (A vs. D)
Grade spread
B 4 · C 1 · F 5
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ALLO is the first available peer comparator.
Off-the-shelf CAR T development comparator from the prior baseline. Donor-derived product design and a different pipeline limit direct valuation comparisons.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
FATE
Fate Therapeutics
ALLO
Allogene Therapeutics
Grade
A
C
Momentum
95
96
Value
41
41
Sentiment
89
54
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs ALLO
FATE / ALLO
Grade Position
Above peers
FATE vs. peer average (A vs. D)
92/100
Momentum
95
ALLOValue
41
FATESentiment
89
FATERotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs FATE
ALLO is the first peer returned for this comparison set.